Up-to-Date Meta-Analysis Statins in Stroke Prevention and Carotid Atherosclerosis : Systematic Review and

Up-to-Date Meta-Analysis Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Print ISSN: 0039-2499. Online ISSN: 1524-4628 Copyright © 2004 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Stroke doi: 10.1161/01.STR.0000147965.52712.fa 2004;35:2902-2909; originally published online October 28, 2004; Stroke. http://stroke.ahajournals.org/content/35/12/2902 World Wide Web at: The online version of this article, along with updated information and services, is located on the

[1]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[2]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[3]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[4]  J. Roh,et al.  Low Concentration of Serum Total Cholesterol Is Associated With Multifocal Signal Loss Lesions on Gradient-Echo Magnetic Resonance Imaging: Analysis of Risk Factors for Multifocal Signal Loss Lesions , 2002, Stroke.

[5]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[6]  Allen J. Taylor,et al.  ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness , 2002, Circulation.

[7]  M. Ezekowitz,et al.  Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy , 2002, Circulation.

[8]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[9]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[10]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[11]  P. Amarenco.  Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction , 2001, Neurology.

[12]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[13]  K. Yano,et al.  Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study , 2001, The Lancet.

[14]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[15]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[16]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[17]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[18]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[19]  K. Teo,et al.  Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) , 2000, Circulation.

[20]  Huang Chaolian.  Effect of simvastatin on coronary atheroma , 2000 .

[21]  A. Brett.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[22]  Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[23]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[24]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[25]  M. Pahor,et al.  Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. , 1999, Hypertension.

[26]  MahmoudZureik,et al.  Cross-Sectional and 4-Year Longitudinal Associations Between Brachial Pulse Pressure and Common Carotid Intima-Media Thickness in a General Population , 1999 .

[27]  P Ducimetière,et al.  Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study. , 1999, Stroke.

[28]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[29]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[30]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[31]  A. Zwinderman,et al.  B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). , 1998, Journal of the American College of Cardiology.

[32]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[33]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[34]  H. White,et al.  Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .

[35]  G. Gamble,et al.  Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. , 1998, Circulation.

[36]  R. D'Agostino,et al.  Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. , 1997, The New England journal of medicine.

[37]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[38]  C. Furberg,et al.  Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.

[39]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[40]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[41]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[42]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[43]  D. Kromhout.  Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[44]  D. Waters,et al.  Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. , 1995, Circulation.

[45]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[46]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[47]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[48]  C. Furberg,et al.  Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke , 1995 .

[49]  N. Cook,et al.  Implications of small reductions in diastolic blood pressure for primary prevention. , 1995, Archives of internal medicine.

[50]  G. Levine,et al.  Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. , 1995, The New England journal of medicine.

[51]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). , 1995, The American journal of cardiology.

[52]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[53]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[54]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[55]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[56]  A. Gotto,et al.  Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. , 1994, The American journal of cardiology.

[57]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[58]  Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. , 1993, American Journal of Cardiology.

[59]  C. Furberg,et al.  Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. , 1992, Controlled clinical trials.

[60]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[61]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[62]  P A Wolf,et al.  Epidemiology of stroke. , 2004 .